Skip to content
Forge Biologics
  • About
    • About
    • Mission & Approach
    • Leadership
    • Board
  • Services
    • Manufacturing Services
    • Technology
  • Science
    • Science
    • Pipeline
    • About Gene Therapy
    • FBX-101 for Krabbe Disease
  • Careers
  • News & Insights
    • News
    • Events
    • Insights
    • Media Kit
  • Connect

Forge Biologics bags $120M round as it looks to scale AAV manufacturing for Krabbe disease treatment

Posted on April 29, 2021 (July 14, 2021) by K Terry Smith
Read In Full: https://sciencebusiness.technewslit.com/?p=40642
0/5 (0 Reviews)
Posted in Biologics News, In the news, Krabbe DiseaseTagged IND, investigational new drug application

Post navigation

 Forge Biologics Announces Closing of $120 Million Series B FinancingGene therapy ‘development engine’ scores $120M to beef up contract manufacturing 
Copyright Forge Biologics - All Rights Reserved Cookie Notice | Privacy Policy

I agree to the Cookie Notice and Privacy Policy

I agree